CD221 Antibody
- Known as:
- CD221 Antibody
- Catalog number:
- XW-7274
- Product Quantity:
- 0.05 mg
- Category:
- -
- Supplier:
- Prosci
- Gene target:
- CD221 Antibody
Related genes to: CD221 Antibody
- Gene:
- IGF1R NIH gene
- Name:
- insulin like growth factor 1 receptor
- Previous symbol:
- -
- Synonyms:
- JTK13, CD221, IGFIR, MGC18216, IGFR
- Chromosome:
- 15q26.3
- Locus Type:
- gene with protein product
- Date approved:
- 1988-07-07
- Date modifiied:
- 2019-04-23
Related products to: CD221 Antibody
Related articles to: CD221 Antibody
- Pregnancy-associated plasma protein A (PAPPA) cleaves insulin-like growth factor (IGF) binding proteins (IGFBP) 2, 4, 5, releasing IGF1. PAPPA is overexpressed in polycystic kidneys and its genetic elimination or suppression by mouse Ansh Labs PAPPA-mAb, which blocks IGFBP4 but not IGFBP5 cleavage, ameliorates polycystic kidney disease (PKD) in Pkd1 mice. Here, we sought to generate human pan-selective PAPPA-mAbs and test their efficacy in models of advanced and early PKD, using a wide range of doses in mice. - Source: PubMed
Publication date: 2026/09/23
Hu ErdingGardener Matthew JWang XiaofangLuo GuizhenKotzer ChuckJiang LiMallick EmilySrinivasan ArunOuro-Gnao LarissaFirczuk HelenaChandler ShaneChung Chun-WaGoswami PanchaliMadi SaaussanLenhard StephenAlsaid HasanDoan MinhNanayakkara KaviniSwerdlow Daniel IRoberts JulietTorres Vicente E - Thyroid eye disease (TED) is a debilitating autoimmune condition. Teprotumumab, the first approved biologic for TED, is effective but costly. Veligrotug, an insulin-like growth factor-1 receptor (IGF-1 R) inhibitor requiring fewer infusions, is a recently approved alternative with a confirmed wholesale acquisition cost and confirmed pivotal-trial efficacy. - Source: PubMed
Publication date: 2026/09/21
Li ZhengxuanWeng Christina YChen HuaTatar Moosa - To explore the roles of insulin-like growth factor 1 receptor (IGF1R) and thyroid-stimulating hormone receptor (TSHR) in extraocular muscle pathology. - Source: PubMed
Publication date: 2026/09/18
Chen Kuan-YingLin Chia-ChenChen Wan-JuLai Chun-Chieh - Drug repurposing can accelerate the identification of novel therapeutic candidates for rare cancers such as inflammatory breast cancer (IBC), an aggressive type with limited therapeutic options. Here, we report an experimental validation study of compounds previously identified through two computational approaches: Literature Wide Association Studies (LWAS) and Gene Reversal Rate (GRR). Candidate compounds were tested using orthogonal cell viability assays in 2D models across IBC and non-IBC cell lines. In the SUM149 IBC cell line, repurposed compounds predicted from LWAS achieved a 70% success rate, with several showing nanomolar potency, while those predicted from GRR showed a 38% success rate. Through systematic combination screening in both 2D and 3D-spheroid SUM149 models, we identified novel synergistic compound pairs targeting crosstalk between IGF-1R, EGFR and PI3K/Akt/mTOR pathways, with high synergy scores across multiple reference models. Using these combinations, western blott analysis revealed significant suppression in the phosphorylation of key signaling proteins and downstream effectors, while wound healing assays showed reduced cell migration with some combination treatments, suggesting effective pathway inhibition. To further validate these findings at the transcriptional level, RNA-Seq analysis in SUM149 cells confirmed that the GRR drug combinations significantly reversed the IBC gene expression signature (IBC-GES) and identified several clinically relevant genes whose expression was significantly altered. Together, these findings validate our computational predictions and identify candidate combination strategies that may help address therapeutic resistance in IBC. This integrated computational-experimental approach establishes a pipeline for systematic drug repurposing and highlights novel therapeutic combinations for further investigation. - Source: PubMed
Publication date: 2026/09/16
Salim Esraa AJi XiaojiaTarpley MichaelDixon Maria SZheng WeifanScott John EWilliams Kevin P - -associated skeletal dysplasias affect cartilage extracellular matrix and endochondral growth, but patient growth-plate tissue is largely inaccessible. We generated chondrogenically induced urine-derived cells (chUDCs) from three individuals with heterozygous pathogenic variants and three healthy controls. Classical differentiation was assessed by Alcian blue and Alizarin red staining, bulk RNA sequencing compared patient-derived and control chUDCs, and single-cell RNA sequencing was performed in two patient-derived lines. -mutant chUDCs retained overt chondrogenic and osteogenic staining capacity without a clear patient-control separation. In contrast, bulk RNA sequencing identified a small set of consistently differential extracellular-matrix remodeling genes enriched for matrix and ossification-related programs; and remained significant in leave-one-donor-out, age-adjusted and cell-composition-adjusted models. Single-cell profiling resolved multiple chUDC states, including chondrogenic, fibroblastic extracellular-matrix, IGF1R-high, and osteogenic-associated states. IGF1 co-treatment was associated with reduced osteogenic-associated module scores and increased fibroblastic/anabolic extracellular-matrix programs. Because no IGF1-treated control-donor line was profiled, IGF1-associated changes are reported as exploratory and are not claimed to be -specific. These findings support chUDCs as a non-invasive system for exploring selected transcriptional programs relevant to cartilage biology and growth-factor responsiveness in -associated growth disorders. - Source: PubMed
Publication date: 2026/09/01
Schulz AlexanderSchubert MichaelBrockmann Emily MEkici Arif BUebe SteffenThiel Christian T